SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Cue Health
(Nasdaq: HLTH), a healthcare technology company, today announced
that it is teaming up with award-winning actor and producer Gal
Gadot to bring Cue - the new, essential smart device for your
health - to life in its inaugural Super Bowl® commercial on
Sunday, February 13, 2022. In the new
spot, Cue joins the other smart devices in the home and showcases
her differentiated capabilities as the newcomer whose job is to
protect the family's most valuable asset: their health.
@CueHealth teams up with award-winning actor and producer Gal Gadot
to bring Cue – the new, essential smart device for your health – to
life in its inaugural Big Game commercial this Sunday.
"This Super Bowl Sunday, I'm excited to introduce more people to
Cue, an empowering smart device for your health that gives me hope
for a healthier future," said Gal Gadot.
"Cue's mission has always been to empower people to live their
healthiest lives," said Ayub
Khattak, Chief Executive Officer of Cue Health. "Together
with the one and only Gal Gadot, Cue comes to life on one of the
world's biggest stages as the heroic, essential smart device that
people can rely on to manage their own health and the health of
their families."
Cue's molecular test is the most accurate at-home test for
COVID-19*, delivering results to a mobile smart device in 20
minutes using the Cue Health App. Cue's test cartridges and
components are proudly made in the USA. Cue+TM members can connect
with a physician through 24/7 in-app virtual care to get the
answers they are seeking about their test results and other health
concerns. Looking ahead, Cue is poised to usher in the digital
transformation of personalized healthcare with new diagnostic tests
- including for respiratory illnesses, sexual diseases,
cardiometabolic health, and more - all of which will be compatible
with the powerful, connected Cue Reader.
Before the Big Game, Cue is also making its testing platform
easier than ever to access with lower pricing on Cue+ memberships
and COVID-19 tests for both existing members and new customers.
"In an effort to make Cue more accessible to more people, today
we're proud to introduce new, lower pricing for Cue+ memberships
and a la carte COVID-19 tests," added Clint
Sever, Chief Product Officer of Cue Health.
Cue's products are available now on shop.cuehealth.com.
Cue Health's Super Bowl commercial was produced in collaboration
with Doner LA.
Please download announcement press assets HERE
About Cue Health
Cue Health (Nasdaq: HLTH) is a
healthcare technology company that makes it easy for individuals to
access health information and places diagnostic information at the
center of care. Cue Health enables people to manage their health
through real-time, actionable, and connected health information,
offering individuals and their healthcare providers easy access to
lab-quality diagnostics anywhere, anytime, in a device that fits in
the palm of the hand. Cue Health's first-of-its-kind COVID-19 test
was the first FDA-authorized molecular diagnostic test for at-home
and over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organization, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements". The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including those related
to the expected future diagnostic test menu and the factors
discussed in the "Risk Factors" section of the Form 10-Q dated
November 10, 2021 filed by Cue with
the SEC. Any forward-looking statements contained in this press
release are based on the current expectations of Cue's management
team and speak only as of the date hereof, and Cue specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
These products have not been FDA cleared or approved; but
have been authorized by FDA under an Emergency Use Authorization
(EUA). These products have been authorized only for the detection
of nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. The emergency use of these products is only authorized
for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
*Based on clinical study results submitted to FDA for other
EUA molecular home tests.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gal-gadot-voices-the-new-essential-smart-device-for-your-health-in-cues-inaugural-super-bowl-commercial-301480664.html
SOURCE Cue Health Inc.